Login to Your Account

Potential Deal Value Of $440M

Isis Gets $45M Up Front In Deal With Ortho On Diabetes Drugs

By Trista Morrison

Friday, September 14, 2007
Four months after licensing a preclinical, second-generation antisense drug for high cholesterol to Bristol-Myers Squibb Co. in a deal worth up to $192 million, Isis Pharmaceuticals Inc. is at it again. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription